Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,762 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Sale · Disposed 1,000 · Balance 26,762 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avid Bioservices, Inc.
Report date February 05, 2025 · Filed February 07, 2025
Section 16 reporting ended · disclosed 2025-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 1
1 source rowRow 1 · 2025-02-05 · Disposition to issuer · Disposed 45,611 · Balance 0 F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.06 · Expires 2027-12-03 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-05 · Disposition to issuer · Disposed 19,403 · Balance 0 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-05 · Disposition to issuer · Disposed 8,147 · Balance 0 F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub.
F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 00:57 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 1,000 | $71.53 | $71,530.00 |
DisclosureSEC source: 0001819879-26-000006 · wk-form4_1789433836.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,762 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2026. Read SEC document |
| May 21, 2026 Filed Jun 11, 2026 01:10 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001819879-26-000003 · wk-form4_1781140220.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,762 F1 · kind: Represents a restricted stock award that will vest in full on May 21, 2027. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:42 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,675 | $88.87 | $1,304,167.25 |
DisclosureSEC source: 0001819879-25-000004 · wk-form4_1755722518.xml · nonDerivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,405 F2 · price: The shares were sold in multiple trades at prices ranging from $88.74 to $89.39. The price reported above reflects the weighted average sales price. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:42 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,865 | $89.76 | $616,202.40 |
DisclosureSEC source: 0001819879-25-000004 · wk-form4_1755722518.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,080 F1 · price: The shares were sold in multiple trades at prices ranging from $89.75 to $89.90. The price reported above reflects the weighted average sales price. Read SEC document |
| May 22, 2025 Filed May 27, 2025 22:16 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001819879-25-000002 · wk-form4_1748384174.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,945 F1 · kind: Represents a restricted stock award that will vest in full on May 22, 2026. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:40 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerRestricted Stock Units · Derivative | 8,147 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001683168-25-000863 · ownership.xml · derivative · entry 3 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,147 shares Expires not disclosed F5 · shares: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6 · price: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.exercise_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.expiration_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:40 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerStock Option (right to buy) · Derivative | 19,403 | Not disclosed Strike: $11.06 | Not disclosed |
DisclosureSEC source: 0001683168-25-000863 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,403 shares Expires 2027-12-03 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 19:40 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Disposition to issuerCommon Stock, $0.001 par value | 45,611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-25-000863 · ownership.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2 · price: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 19:50 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 8,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-008805 · ownership.xml · derivative · entry 3 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,147 Underlying: Common Stock · 8,147 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 19:50 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 26,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-008805 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,756 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 19:50 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 26,756 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-008805 · ownership.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| May 21, 2024 Filed May 24, 2024 00:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 4,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001819879-24-000002 · wk-form4_1716508923.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,609 F1 · kind: Represents a restricted stock award that will vest in full on May 21, 2025. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 19:34 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 26,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-23-008946 · ownership.xml · derivative · entry 3 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,756 Underlying: Common Stock · 26,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 19:34 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 9,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-23-008946 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 19:34 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 9,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-23-008946 · ownership.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| December 03, 2023 Filed Dec 5, 2023 19:33 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 1,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-23-008640 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,612 Underlying: Common Stock · 1,537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F1 · kind: Each Restricted Stock Unit represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units granted to the reporting person on December 3, 2020, vested in three (3) equal annual installments beginning December 3, 2021 and each year thereafter until December 3, 2023. F2 · derivative.expiration_date: The Restricted Stock Units granted to the reporting person on December 3, 2020, vested in three (3) equal annual installments beginning December 3, 2021 and each year thereafter until December 3, 2023. Read SEC document |
| December 03, 2023 Filed Dec 5, 2023 19:33 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 1,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-23-008640 · ownership.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064155 · tm2316872-4_4seq1.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,199 F1 · kind: Represents a restricted stock award that will vest in full on May 23, 2024. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 20:02 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 9,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-22-008499 · ownership.xml · derivative · entry 3 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,149 Underlying: Common Stock · 9,612 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 20:02 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 4,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-22-008499 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537 Underlying: Common Stock · 4,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 20:02 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 4,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-22-008499 · ownership.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| December 03, 2022 Filed Dec 6, 2022 19:41 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionRestricted Stock Units · Derivative | 1,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-22-008225 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,169 Underlying: Common Stock · 1,537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F1 · kind: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 3, 2020, vest in three (3) equal annual installments beginning December 3, 2021 and each year thereafter until fully-vested, subject to the reporting person's continuous service to the Issuer on such vesting dates. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 3, 2020, vest in three (3) equal annual installments beginning December 3, 2021 and each year thereafter until fully-vested, subject to the reporting person's continuous service to the Issuer on such vesting dates. Read SEC document |
| December 03, 2022 Filed Dec 6, 2022 19:41 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 1,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-22-008225 · ownership.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:26 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 10,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004394 · form4-04292022_030449.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,334 F1 · kind: Represents a restricted stock award that will vest in full on April 27, 2023. Read SEC document |
| December 20, 2021 Filed Dec 23, 2021 01:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 1,072 | $46.47 | $49,819.59 |
DisclosureSEC source: 0001415889-21-006192 · form4-12222021_051238.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,785 Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:35 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 4,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-21-006442 · ownership.xml · derivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,706 Underlying: Common Stock · 4,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F3 · derivative.exercise_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. F3 · derivative.expiration_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 19:13 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 1,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-21-006177 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,074 Underlying: Common Stock · 1,537 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 3, 2020, vest in three (3) equal annual installments beginning December 3, 2021 and each year thereafter until fully-vested, subject to the reporting person's continuous service to the Issuer on such vesting dates. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 3, 2020, vest in three (3) equal annual installments beginning December 3, 2021 and each year thereafter until fully-vested, subject to the reporting person's continuous service to the Issuer on such vesting dates. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 19:13 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | Exercise / conversionCommon Stock, $0.001 par value | 1,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-006177 · ownership.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:39 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 9,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001657 · form4-03252021_010347.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,713 F1 · kind: Represents a restricted stock award that will vest in full on March 23, 2022. Read SEC document |
| March 16, 2021 Filed Jan 28, 2022 21:43 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 1,500 | $33.22 | $49,830.00 |
DisclosureSEC source: 0001415889-22-000853 · form5-01282022_010114.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,285 Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 20:07 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantRestricted Stock Units · Derivative | 4,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-20-004192 · ownership.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,611 Underlying: Common Stock · 4,611 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's Common Stock. F3 · derivative.exercise_date: One-third of the RSUs granted to the reporting person shall vest on December 3, 2021 and on each one-year anniversary thereafter until fully vested, subject to the reporting person's continuous service to the Issuer on such vesting dates. F3 · derivative.expiration_date: One-third of the RSUs granted to the reporting person shall vest on December 3, 2021 and on each one-year anniversary thereafter until fully vested, subject to the reporting person's continuous service to the Issuer on such vesting dates. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 20:07 UTC | Avid Bioservices, Inc. CDMO · Entity 83494 | GrantStock Option (right to buy) · Derivative | 19,403 | $0.00 Strike: $11.06 | $0.00 |
DisclosureSEC source: 0001683168-20-004192 · ownership.xml · derivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,403 Underlying: Common Stock · 19,403 shares Expires 2027-12-03 F1 · derivative.exercise_date: One-third of the stock options granted to the reporting person shall vest on December 3, 2021 and on each one-year anniversary thereafter until fully vested, subject to the reporting person's continuous service to the Issuer on such vesting dates. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Option (right to buy) · Derivative | 16,024 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002068 · form4-08072020_040806.xml · derivative · entry 2 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,024 Underlying: Common Stock · 16,024 shares Expires 2029-08-05 F2 · derivative.exercise_date: The option will vest and become exercisable as to 50% of the total shares on August 5, 2021 and the remaining 50% of the total shares on August 5, 2022. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 7,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002068 · form4-08072020_040806.xml · nonDerivative · entry 1 Thoma Jeanne · CIK 0001819879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,421 F1 · kind: Represents a restricted stock award that will vest as to 50% of the total shares on August 5, 2021 and the remaining 50% of the total shares on August 5, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.